DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for gliomatosis cerebri — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGliomatosis cerebri maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gliomatosis cerebri is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tripartite motif containing 24 (TRIM24) — TRIM24 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet benzyloxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YBM · 1.46 Å · ligand N-{6-[3-(benzyloxy)phenoxy]-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl}-3,4-dimethoxybenzenesulfonamide (4BJ). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2003 · 23 citations
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri
AbstractAccording to the World Health Organization classification, gliomatosis cerebri (GC) is defined by diffuse neoplastic glial cell infiltration involving at least two lobes of the brain and preserving the underlying neural structures, without individual tumoral mass.1 Because of the diffuse characteristics of the lesion, surgery is often limited to a diagnostic biopsy. Radiotherapy necessarily involves a large volume (most often the whole brain) and results in substantial toxicity. However, a 38-month median survival time has been reported with this treatment and it has been suggested that it may benefit at least some patients.2,3⇓ Up-front chemotherapy has seldom been tested in GC. Recently, …
Gliomatosis cerebri: características clinicopatológicas, de neuroimagen y resultados del tratamiento con radioterapia
AbstractINTRODUCTION: Gliomatosis cerebri is a rare form of malignant neoplastic glial transformation that involves large areas of the central nervous system. OBJECTIVE: To describe clinical manifestations, pathognomonic neuroimaging findings and results of radiotherapy of gliomatosis cerebri. PATIENTS AND METHODS: We review clinical records and neuroimaging studies of two patients with gliomatosis cerebri identified from the files of brain tumor registries of two university hospitals. One patient underwent radiotherapy after surgery. RESULTS: Clinical manifestations and evolution were totally different in both patients despite the fact that both tumors had the same extension on neuroimaging studies. Magnetic resonance imaging revealed the extent of the lesion in both cases, comprising both cerebral hemispheres. Histopathological study revealed G-I and G-II astrocytomas. The patient treated with whole brain irradiation experienced clinical improvement and involution of the brain tumour on neuroimaging studies, and survived 20 months after surgery. CONCLUSIONS: Clinical manifestations of gliomatosis cerebri are protean. Therefore, neuroimaging studies and histopathological analysis of brain tissue allow the correct diagnosis. Radiotherapy may improve neurological function in some patients. However, it is necessary to compare the long-term evolution of treated and non-treated patients to evaluate clinical efficacy of radiotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
